Intellipharmaceutics International Inc. IPCIF
0.15 +0.15
Nov 25, 2024, 3:00 PM EST
0.15 Day range 0.15
0.15 52-week range 0.15
- Market cap
- 4.96M
- EPS (ttm)
- -0.09
- P/E ratio
- -1.67
- Day's range
- 0.15 – 0.15
- 52-week range
- 0.15 – 0.15
- Earnings date
- Nov 18, 2024
2Y 0.0000 (0.00%)
Next earnings
Nov 18, 2024
Expected Nov 18, 2024. Consensus EPS estimate 0.00.
Financials — quick view
IPCIF Revenue — quarterly 29.68K
IPCIF Net income — quarterly -874.73K
IPCIF EPS — quarterly -0.02
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 18, 2024 | Aug 1, 2024 | 0.00 | — | — | — |
| Sep 6, 2024 | May 1, 2024 | 0.00 | — | — | — |
| Oct 16, 2023 | Aug 1, 2023 | 0.00 | — | — | — |
| Jul 14, 2023 | May 1, 2023 | 0.00 | — | — | — |
| Jun 6, 2023 | Feb 1, 2023 | 0.00 | — | — | — |
News
Analyzing Nuvo Pharmaceuticals (OTCMKTS:MRVFF) and Intellipharmaceutics International (OTCMKTS:IPCIF) 
Reviewing Intellipharmaceutics International (OTCMKTS:IPCIF) & Neoleukin Therapeutics (NASDAQ:NLTX) 
Intellipharmaceutics Announces Downgrade to OTC Expert Market 
Intellipharmaceutics International Inc. Announces Transfer of Listing to NEX and New Stock Option Plan 
Intellipharmaceutics Announces Cease Trade Order 
Intellipharmaceutics Announces Its Expected Delay in Filing Annual Audited Financial Statements and Annual Information Form 
Intellipharmaceutics International Inc. Announces Stock Option Grant 
Intellipharmaceutics International Inc. Receives Conditional Approval to List on the TSX Venture Exchange 
Intellipharmaceutics Announces Third Quarter 2023 Results 
Intellipharmaceutics Reports Director Election Results
Your note
Sign in to keep a note on IPCIF — it syncs with the Stock Master app.